Name | Iniparib |
Description | Iniparib (BSI-201) (BSI-201) , a PARP1 inhibitor, exhibits potency in triple-negative breast Y (TNBC). |
Cell Research | Cells are exposed to various concentrations of BSI-201 for 5, and 9 days in the presence or absence of buthionine sulfoxamide (BSO). After treatment, cell proliferation is measured by CellTiter-Glo assay.(Only for Reference) |
In vivo | In 855-2 cells, the combination of BSI-201 (120 μM) and buthionine sulfoximine induced cell death up to 95%, which was similar to the effect on other human tumor cells. In E-ras 20 cells, BSI-201 inhibited cell growth, and its effect was enhanced 20-fold when combined with buthionine sulfoximine. BSI-201 (100 μM) inhibited the repair of ionizing radiation-induced single-strand breaks (SSBs) in human lymphocyte cell lines. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 14.6 mg/mL (50 mM) DMSO : 85 mg/mL (291.07 mM), Sonication is recommended.
|
Keywords | PARP | Inhibitor | Iniparib | BSI201 | inhibit | BSI 201 | NSC 746045 | IND 71677 | NSC746045 | Influenza Virus | IND71677 | poly ADP ribose polymerase |
Inhibitors Related | Rifampicin | Acetylcysteine | α-Vitamin E | Nitazoxanide | Curcumin | Naringenin | Olaparib | Salcomine | Crystal Violet | β-Cyclodextrin |
Related Compound Libraries | Bioactive Compound Library | Anti-Ovarian Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |